|
Characteristic
|
Total (n = 67)
|
Daptomycin dose (mg/kg)
| |
|---|
|
≤ 8 (n = 41)
|
> 8 (n = 26)
|
P value
|
|---|
|
14-day mortality
|
11 (16.4%)
|
6 (14.6%)
|
5 (19.2%)
|
0.74
|
|
28-day mortality
|
24 (35.8%)
|
13 (31.7%)
|
11 (42.3%)
|
0.44
|
|
In-hospital mortality
|
33 (49.3%)
|
20 (48.8%)
|
13 (50.0%)
|
0.92
|
|
ICU patients (n = 41)
|
28 (68.3%)
|
17/24 (70.8%)
|
11/17 (64.7%)
|
0.74
|
|
Infection-related death
|
9 (13.4%)
|
5 (12.2%)
|
4 (15.4%)
|
0.73
|
|
ICU patients (n = 41)
|
7 (17.1%)
|
4/24 (16.7%)
|
3/17 (17.6%)
|
>0.99
|
|
Clinical success
|
52 (77.6%)
|
32 (78.0%)
|
20 (76.9%)
|
0.91
|
|
All bacteremia (n = 54)
|
43 (79.6%)
|
27/32 (84.4%)
|
16/22 (72.7%)
|
0.32
|
|
MRSA (n = 38)
|
28 (73.7%)
|
18/23 (78.3%)
|
10/15 (66.7%)
|
0.47
|
|
Vancomycin MIC ≥ 2 μg/mL (n = 24)
|
19 (79.2%)
|
13/14 (92.9%)
|
6/10 (60%)
|
0.12
|
|
VRE (n = 18)
|
12 (66.7%)
|
7/12 (58.3%)
|
5/6 (83.3%)
|
0.60
|
|
Endocarditis (n = 11)
|
6 (54.5%)
|
2/3 (66.7%)
|
4/8 (50.0%)
|
>0.99
|
|
Catheter-related bacteremia (n = 16)
|
15 (93.8%)
|
10/11 (90.9%)
|
5/5 (100%)
|
0.59
|
|
cSSTI (n = 16)
|
14 (87.5%)
|
7/9 (77.8%)
|
7/7 (100%)
|
0.48
|
|
Bone & joint infection (n = 9)
|
6 (66.7%)
|
4/6 (66.7%)
|
2/3 (66.7%)
|
>0.99
|
|
Microbiological success
|
55 (82.1%)
|
36 (87.8%)
|
19 (73.1%)
|
0.19
|
|
Adverse events
| | | | |
|
Cytopenia
|
47 (70.2%)
|
28 (68.3%)
|
19 (73.1%)
|
0.68
|
|
Renal dysfunction
|
14 (20.9%)
|
8 (19.5%)
|
6 (23.1%)
|
0.73
|
|
Elevated AST/ALT
|
20/66 (30.3%)
|
12/41 (29.3%)
|
8/25 (32.0%)
|
0.82
|
|
CPK elevations
| | | | |
|
Any
|
16 (29.2%)
|
7/37 (18.9%)
|
9/24 (37.5%)
|
0.11
|
|
By definition
|
4/61 (6.6%)
|
0/37 (0%)
|
4/24 (16.7%)
|
0.02
|
-
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; cSSTI, complicated skin and soft-tissue infection; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant S. aureus; VRE, vancomycin-resistant enterococci.
